Consistent with a previous finding14, we found that the expression levels of LATS1 and LATS2, at the mRNA and protein level, were significantly higher in patients with CML, suggesting their roles in the pathogenesis of CML. The gene discussed is LATS2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.